In the past 2 decades, significant progress has been made in the therapeutic strategy for pulmonary hypertension (PH). In pulmonary arterial hypertension (PAH), we are able to use agents targeting 3 separate pathogenic pathways, including phosphodiesterase-5 inhibitors, endothelin receptor antagonists, prostaglandins, and more recently, soluble guanylate cyclase stimulators and selective IP prostacyclin receptor agonist, all of which could improve hemodynamics and prognosis. Furthermore, several studies have indicated that balloon pulmonary angioplasty (BPA) improves hemodynamics and prognosis in patients with distal-type CTEPH. Also, several national registry studies on PH, such as FRENCH registry, REVEAL registry, and Japan PH registry, have been published, demonstrating recent therapeutic strategy and prognosis in PH patients. However, evidence is still lacking for several clinical issues, including efficacy of upfront combination therapy in PAH patients, efficacy of immunosuppression therapy for PAH associated with connective tissue disease, PH in adult congenital heart disease, therapeutic strategy for PH associated with lung diseases, cross-national difference of effects of BPA, and so on. In Japan, registries on each PH class have recently started. Furthermore, recent progress in information and communication technology (ICT) has enabled us to utilize “big data”, such as clinical information, DPC data, epidemiological data, and national database, which are potentially useful to solve the clinical questions. In this session, we will discuss on the current status and future perspective of “registry” and “big data” in the field of PH.